Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer (NYSE: ITGR) will webcast a conference call to discuss fourth quarter and full year results for the period ended Dec. 31, 2025, on Thursday, Feb. 19, 2026 at 8 a.m. CT / 9 a.m. ET.
The company will issue a news release with financial results prior to the call. Domestic dial-in: (800) 715-9871; international dial-in: (646) 307-1963; conference ID: 3120125. Webcast registration is available via the Integer investor site and an audio replay will be available for seven days by dialing (800) 770-2030 or (609) 800-9909 using the same conference ID. Live and archived replay will be on Integer's Investor Relations website.
Integer (NYSE: ITGR) will exhibit at the North American Neuromodulation Society Annual Meeting in Las Vegas from Jan. 22–25, 2026. Visit booth #115 to see Integer’s work on neuromodulation and miniaturized active implantable medical devices (AIMDs) aimed at accelerating development timelines and reducing risk for device makers.
Integer will highlight full-system capabilities—from high-performance batteries to integrated implantable pulse generators and lead systems—and showcase the Xcellion® Gen 3 Fast Charge Lithium Ion battery, which offers best-in-class runtime and recharges in as little as 30 minutes.
Integer (NYSE: ITGR) said members of its executive leadership team will participate in two investor conferences in early December 2025.
Scheduled appearances: Piper Sandler 37th Annual Healthcare Conference at 8:00 a.m. ET on Tuesday, Dec. 2, 2025, and Citi 2025 Global Healthcare Conference at 9:45 a.m. ET on Wednesday, Dec. 3, 2025. Live webcasts and replays will be available under News & Events in the Investor Relations section at investor.integer.net.
Integer Holdings Corporation (NYSE: ITGR) announced on November 4, 2025 that its Board authorized a $200 million share repurchase program for the company's outstanding common stock. The company said it intends to primarily use cash on hand and free cash flows to fund repurchases. Management may execute repurchases opportunistically or under trading plans, and timing and volume will be at management's discretion. The Board and management characterized the program as reflecting confidence in Integer's strategy and financial position.
Integer (NYSE: ITGR) announced that Payman Khales has assumed the role of President and Chief Executive Officer and joined the company's Board, effective Oct 24, 2025, completing a planned transition announced in April 2025.
Khales joined Integer in 2018, doubled Cardio & Vascular sales in seven years while improving service and profitability, and most recently served as Chief Operating Officer overseeing both business units and global operations. He succeeds Joseph Dziedzic, who is retiring after eight years as CEO and will remain an advisor through Mar 31, 2026 to support the transition.
Integer (NYSE:ITGR) reported third quarter 2025 results for the period ended September 26, 2025, with sales of $467.7M (+8% YoY; organic +7%) and GAAP operating income of $56M. Non-GAAP results showed adjusted operating income $86M (+14%), adjusted EBITDA $106M (+11%), and adjusted EPS $1.79 (+25%).
Total debt rose by $204M to $1.194B, producing a leverage ratio of 3.0x adjusted EBITDA. Product-line drivers included Cardio & Vascular +15% Q and Cardiac Rhythm & Neuromodulation +2% Q; Other Markets fell ~16% Q due to a planned exit. The company updated 2025 guidance and provided preliminary 2026–2027 outlooks, including 2025 sales of $1.84–1.854B and adjusted EPS of $6.29–6.43.
Integer Holdings (NYSE:ITGR) has scheduled its third quarter 2025 earnings conference call for Thursday, October 23, 2025, at 8 a.m. CT / 9 a.m. ET. The company will release its Q3 2025 financial results prior to the call on the same day.
The conference call will be accessible via webcast and telephone, with domestic dial-in at (800) 715-9871 and international dial-in at (646) 307-1963 using Conference ID 3120125. An audio replay will be available for seven days following the call.
Integer Holdings (NYSE:ITGR), a medical device contract development and manufacturing organization, announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference in Boston. The company's executive leadership team will engage in a fireside chat on September 4, 2025, at 3:00 p.m. ET.
Investors can access the live webcast of the presentation through the "News & Events" section on Integer's Investor Relations website at investor.integer.net.
Integer Holdings (NYSE:ITGR) reported strong Q2 2025 results with sales increasing 11% to $476 million. The company's GAAP operating income rose 9% to $59 million, while adjusted operating income grew 15% to $81 million. GAAP diluted EPS from continuing operations increased 18% to $1.04, and adjusted EPS rose 19% to $1.55.
Cardio & Vascular segment led growth with a 24% increase, driven by electrophysiology products and acquisitions. The company raised its 2025 outlook, now expecting adjusted operating income growth of 12% to 16% and adjusted EPS growth of 18% to 23%. Total debt increased to $1.202 billion, primarily for acquisitions and convertible note offering costs.
Integer Holdings (NYSE:ITGR), a leading medical device contract development and manufacturing organization (CDMO), has appointed Michael Coyle to its Board of Directors. Coyle, who brings over 40 years of medical device industry experience, will serve on the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.
Coyle's extensive background includes serving as president and CEO of iRhythm Technologies, executive vice president at Medtronic's cardio and vascular group, and leadership roles at St. Jude Medical and Eli Lilly. He currently serves on the boards of Haemonetics Corporation and BaroPace, and holds six U.S. patents in cardiovascular medical device technologies.